Navigation Links
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer

JERSEY CITY, N.J., May 13, 2013 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of Mr. Eric Sirota as Chief Operating Officer.  Mr. Sirota will be responsible for directing Optimer's corporate strategy with regard to DIFICID®.

"Eric has tremendous experience and has demonstrated leadership in building pharmaceutical brands in the United States and abroad and has dedicated his career to making important new medicines available to the medical profession for the benefit of patients," said Dr. Hank McKinnell , Chairman and CEO of Optimer.  "His appointment fills a significant need at Optimer, and will allow me to focus more of my time on the strategic review process we announced in late February. Keeping the core business functioning well during this process is critical to Optimer and its stockholders, and Eric will be responsible for maintaining and growing our operations."

Mr. Sirota, 51 years old, operated a consultant practice in the healthcare industry for more than three years, consulting with numerous pharmaceutical companies and healthcare service organizations to develop new, and enhance existing, business opportunities with a focus on strategy, operational efficiency and organizational design.  Mr. Sirota has served as a consultant to the Company since March 8, 2013, providing product marketing and business advice to Optimer's Board of Directors and Dr. McKinnell.  In addition, from February 2010 until December 2010, Mr. Sirota served as President of Commercial Services of inVentiv Health, Inc., a provider of clinical, commercial and consulting services to the healthcare industry, where he developed strategies to address the need for integrated analytic, sales and marketing solutions that enhance brand revenue, drive efficiency and lower costs.  Prior to June 2009, Mr. Sirota served as an executive of Pfizer Inc., most recently as Vice President of Pfizer's US Marketing, Commercial Strategy and Innovation and Regional Sales, responsible for the neuroscience and pain franchises.  During his over twenty-year career at Pfizer, Mr. Sirota was responsible for 12 therapeutic areas and more than 25 brands,  including anti-infectives.  He received his B.S. degree in Pharmacy from Rutgers College of Pharmacy and his Master of Business Administration degree from The Wharton School, The University of Pennsylvania.

About Optimer Pharmaceuticals

We are a global biopharmaceutical company currently focused on commercializing our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and Canada, and developing other fidaxomicin products in the United States and worldwide, both by ourselves and with our partners and licensees. DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin has also received marketing authorization in other jurisdictions, including the European Union, where it is marketed under the trade name DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common symptom of Clostridium difficile infection, or CDI. Additional information can be found at

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including, without limitation, statements related to future roles and contributions of Mr. Sirota at Optimer.  Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "seek," "potential," "maximize," "goal" and similar expressions are intended to identify forward-looking statements.   The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to continue driving adoption and use of DIFICID, the effects of changes in Optimer's management, the outcome of Optimer's review of strategic alternatives including a possible sale of the Company, the potential for lawsuits and enforcement proceedings related to the previously disclosed investigations by U.S. authorities and other risks detailed in Optimer's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.

Optimer Pharmaceuticals, Inc.
David Walsey , Vice President, Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark , Senior Vice President
(619) 849-6005


SOURCE Optimer Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Post Your Comments:
(Date:11/30/2015)... 30, 2015 Nautilus Medical Inc. today announced ... platform ( ). The release of MatrixRay to ... 2015 (Radiology Society North America) in Chicago ... U.S. --> --> ... access to radiology studies worldwide via a peer-to-peer exchange ...
(Date:11/30/2015)... 30, 2015 ... adds a 2015 publication on ... 2015 with comprehensive analysis of recent ... deal types, such as Mergers & ... . --> ...
(Date:11/30/2015)... , Nov. 30, 2015  The ... norm in U.S. medical imaging is on ... popular accountable care payer-provider contracts are set ... in their wake, alter provider-vendor relationships. The ... will push forward new purchasing frameworks in ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... While powdered supplements ... in wasted time. Fortunately, an inventor from Chesterfield, Va., has found an easy to ... keep the scoop used to measure powdered contents in a canister or other container ...
(Date:11/30/2015)... ... November 30, 2015 , ... Volpara Solutions ... density assessment and enterprise analytics solutions, here at the 101st Annual Radiological ... booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements of volumetric ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US ... is a long-term resorbable surgical mesh intended to support and reinforce soft tissue ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members ... Juan Beauty Show held on November 8th and 9th at the Puerto Rico Convention ... hair artists, renowned beauticians and top of the line fashion journalists. The San Juan ...
Breaking Medicine News(10 mins):